Group sequential testing for cluster randomized trials with time-to-event endpoint

被引:0
作者
Li, Jianghao [1 ]
Jung, Sin-Ho [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Sch Med, Durham, NC 27705 USA
关键词
alpha spending function; dependent increment; expected sample size; intracluster correlation coefficient; log-rank test; variable cluster size; MAXIMUM DURATION; LOGRANK TESTS; DESIGN;
D O I
10.1111/biom.13498
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose group sequential methods for cluster randomized trials (CRTs) with time-to-event endpoint. The alpha spending function approach is used for sequential data monitoring. The key to this approach is determining the joint distribution of test statistics and the information fraction at the time of interim analysis. We prove that the sequentially computed log-rank statistics in CRTs do not have independent increment property. We also propose an information fraction for group sequential trials with clustered survival data and a corresponding sample size determination approach. Extensive simulation studies are conducted to evaluate the performance of our proposed testing procedure using some existing alpha spending functions in terms of expected sample size and maximal sample size. Real study examples are taken to demonstrate our method.
引用
收藏
页码:1353 / 1364
页数:12
相关论文
共 50 条
[31]   Multi-arm multi-stage clinical trials for time-to-event outcomes [J].
Dixit, Vaidehi ;
Mitra, Priyam ;
Simonsen, Katy .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2021, 31 (06) :838-851
[32]   Statistical considerations of designs for single-arm proof-of-concept oncology trial with time-to-event endpoint [J].
Zhou, Heng ;
Sun, Linda ;
Wang, Meihua .
CONTEMPORARY CLINICAL TRIALS, 2023, 129
[33]   Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point [J].
Huang, Bo ;
Kuan, Pei-Fen .
PHARMACEUTICAL STATISTICS, 2018, 17 (03) :202-213
[34]   A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: Update [J].
Bratton, Daniel J. ;
Choodari-Oskooei, Babak ;
Royston, Patrick .
STATA JOURNAL, 2015, 15 (02) :350-368
[35]   A propensity score-integrated approach for leveraging external data in a randomized controlled trial with time-to-event endpoints [J].
Chen, Wei-Chen ;
Lu, Nelson ;
Wang, Chenguang ;
Li, Heng ;
Song, Changhong ;
Tiwari, Ram ;
Xu, Yunling ;
Yue, Lilly Q. .
PHARMACEUTICAL STATISTICS, 2024, 23 (05) :645-661
[36]   Implementation of a two-group likelihood time-to-event continual reassessment method using SAS [J].
Salter, Amber ;
Morgan, Charity ;
Aban, Inmaculada B. .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2015, 121 (03) :189-196
[37]   A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules [J].
Guenhan, Burak Kuersad ;
Weber, Sebastian ;
Friede, Tim .
STATISTICS IN MEDICINE, 2020, 39 (27) :3986-4000
[38]   Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer [J].
Le Tourneau, Christophe ;
Michiels, Stefan ;
Gan, Hui K. ;
Siu, Lillian L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5965-5971
[39]   Confirmatory Adaptive Designs for Clinical Trials With Multiple Time-to-Event Outcomes in Multi-state Markov Models [J].
Danzer, Moritz Fabian ;
Faldum, Andreas ;
Simon, Thorsten ;
Hero, Barbara ;
Schmidt, Rene .
BIOMETRICAL JOURNAL, 2024, 66 (07)
[40]   Power and sample-size analysis for the Royston Parmar combined test in clinical trials with a time-to-event outcome [J].
Royston, Patrick .
STATA JOURNAL, 2018, 18 (01) :3-21